Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults.

Grabenstein JD, Manoff SB.

Vaccine. 2012 Jun 22;30(30):4435-44. doi: 10.1016/j.vaccine.2012.04.052. Epub 2012 Apr 26. Review.

PMID:
22542818
2.

Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.

Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD, Silber JL.

J Infect Dis. 2010 Feb 15;201(4):516-24. doi: 10.1086/649839.

PMID:
20092407
3.

Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years.

Manoff SB, Liss C, Caulfield MJ, Marchese RD, Silber J, Boslego J, Romero-Steiner S, Rajam G, Glass NE, Whitney CG, Carlone GM.

J Infect Dis. 2010 Feb 15;201(4):525-33. doi: 10.1086/651131.

PMID:
20088694
4.

Immunogenicity of pneumococcal revaccination in patients with chronic disease.

Davidson M, Bulkow LR, Grabman J, Parkinson AJ, Chamblee C, Williams WW, Lanier AP, Schiffman G.

Arch Intern Med. 1994 Oct 10;154(19):2209-14.

PMID:
7944842
5.

Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine.

Smets F, Bourgois A, Vermylen C, Brichard B, Slacmuylders P, Leyman S, Sokal E.

Vaccine. 2007 Jul 20;25(29):5278-82. Epub 2007 Jun 4.

PMID:
17576024
6.

Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness.

Hammitt LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, Zanis C, Whaley M, Romero-Steiner S, Butler JC, Rudolph K, Hennessy TW.

Vaccine. 2011 Mar 9;29(12):2287-95. doi: 10.1016/j.vaccine.2011.01.029. Epub 2011 Jan 19.

PMID:
21255685
7.

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults.

Shiramoto M, Hanada R, Juergens C, Shoji Y, Yoshida M, Ballan B, Cooper D, Gruber WC, Scott DA, Schmoele-Thoma B.

Hum Vaccin Immunother. 2015;11(9):2198-206. doi: 10.1080/21645515.2015.1030550. Epub 2015 Jul 15.

8.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.

Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, Pugni L, Emini EA, Gruber WC, Scott DA, Principi N.

Clin Vaccine Immunol. 2010 Jun;17(6):1017-26. doi: 10.1128/CVI.00062-10. Epub 2010 Apr 28.

9.

Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review.

Remschmidt C, Harder T, Wichmann O, Bogdan C, Falkenhorst G.

BMC Infect Dis. 2016 Nov 25;16(1):711. Review.

10.

A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults.

Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, Ganesan A, Patel S, Landrum ML, Weintrob A, Agan BK, Medina S, Rahkola J, Hale BR, Janoff EN; Infectious Disease Clinical Research Program HIV Working Group.

J Infect Dis. 2010 Oct 1;202(7):1114-25. doi: 10.1086/656147.

11.

Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease.

Ohshima N, Nagai H, Matsui H, Akashi S, Makino T, Akeda Y, Oishi K.

Vaccine. 2014 Feb 26;32(10):1181-6. doi: 10.1016/j.vaccine.2013.09.060. Epub 2013 Oct 9.

PMID:
24120483
12.

Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines.

Hilleman MR, Carlson AJ Jr, McLean AA, Vella PP, Weibel RE, Woodhour AF.

Rev Infect Dis. 1981 Mar-Apr;3 Suppl:S31-42. Review.

PMID:
7025159
13.

Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.

Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, Peters HV, Knutsen B, Hickel J, Parkinson AJ.

Clin Infect Dis. 2009 Jul 15;49(2):241-8. doi: 10.1086/599824.

PMID:
19522655
14.

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.

Glesby MJ, Watson W, Brinson C, Greenberg RN, Lalezari JP, Skiest D, Sundaraiyer V, Natuk R, Gurtman A, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.

J Infect Dis. 2015 Jul 1;212(1):18-27. doi: 10.1093/infdis/jiu631. Epub 2014 Nov 13.

PMID:
25395187
15.

Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.

Kawakami K, Kishino H, Kanazu S, Toshimizu N, Takahashi K, Sterling T, Wang M, Musey L.

Vaccine. 2016 Jul 19;34(33):3875-81. doi: 10.1016/j.vaccine.2016.05.052. Epub 2016 Jun 10.

16.

Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine.

Waites KB, Canupp KC, Chen YY, DeVivo MJ, Nahm MH.

J Spinal Cord Med. 2008;31(1):53-9.

17.

Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults.

Musher DM, Manoff SB, McFetridge RD, Liss CL, Marchese RD, Raab J, Rueda AM, Walker ML, Hoover PA.

Hum Vaccin. 2011 Sep;7(9):919-28. doi: 10.4161/hv.7.9.15996. Epub 2011 Sep 1.

PMID:
21860256
18.

Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.

Bologa M, Kamtchoua T, Hopfer R, Sheng X, Hicks B, Bixler G, Hou V, Pehlic V, Yuan T, Gurunathan S.

Vaccine. 2012 Dec 14;30(52):7461-8. doi: 10.1016/j.vaccine.2012.10.076. Epub 2012 Nov 2.

PMID:
23123106
19.

[Persistence of antibodies three years after vaccination with the 23-valent pneumococcal vaccine].

Campins Martí M, Casal Lombos J, Tarragó Asensio D, Rodrigo Anoro MJ, Allepuz Palau A, Callís Bracons L.

An Pediatr (Barc). 2003 Feb;58(2):184-7. Spanish.

20.

Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.

Cordonnier C, Ljungman P, Juergens C, Maertens J, Selleslag D, Sundaraiyer V, Giardina PC, Clarke K, Gruber WC, Scott DA, Schmoele-Thoma B; 3003 Study Group.

Clin Infect Dis. 2015 Aug 1;61(3):313-23. doi: 10.1093/cid/civ287. Epub 2015 Apr 13.

Supplemental Content

Support Center